This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug

Stocks in this article: SRPT GSK

Glaxo's own safety data presented Thursday illustrate the lack of a real study blind. Almost 80% of the drisapersen-treated patients reported injection site reactions, compared to 33% of placebo-treated patients.

It's entirely possible patients who knew they were receiving drisapersen were motivated to perform better during the two six-minute walk tests performed at weeks 13 and 25. Likewise, the kids on placebo were unmotivated. It's impossible to quantify with any precision the effect of unblinding might have had on this trial, but the placebo effect needs to be taken into account.

At some point during the course of a clinical trial, the positive impact of the placebo effect runs out. Take a look at the slide again. From week 25 through week 48, continuous drisapersen patients (green line) and placebo patients (blue line) behave exactly the same. The two lines mirror each other, which suggests -- but doesn't prove -- drisapersen might be nothing more than a placebo.

What do we need to be more confident in drisapersen's efficacy? Measurements of dystrophin production. Unfortunately, Glaxo didn't bring these data to Cold Spring Harbor Thursday.

Dystrophin is the protein that helps repair muscles and generally makes muscles function better. DMD patients have a defect in a gene that makes them unable to produce dystrophin. Drisapersen and Sarepta's eteplirsen are designed to "skip over" the defective gene so patients can make partially functional dystrophin.

If the green and blue lines in the slide above truly demonstrate drisapersen's ability to improve walking ability of DMD, we should also see dystrophin production in the drisapersen patients and none in the placebo patients.

Dystrophin was measured in this study but Glaxo says the data are still being crunched and will be presented soon. These dystrophin data are extremely important. I don't believe you can draw any conclusions about drisapersin's efficacy without them.

Here's where I note Sarepta has shown a correlation between dystrophin production and improved walking ability in its small eteplirsen study.

One additional interesting note about the performance of the placebo patients in the Glaxo study, which raises an uncomfortable question for Sarepta.

The placebo patients in the Glaxo study performed better on the six-minute walk test compared to placebo patients in Sarepta's study. One of the tenets of the Sarepta bull thesis is that DMD patients left untreated lose the ability to walk rather rapidly. But the generally stable walking ability of placebo patients in the Glaxo study raise questions about the "realness" of the results seen in the Sarepta study.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs